Morgan Stanley analyst Robert Davies downgraded Sonova to Underweight from Equal Weight with a price target of CHF 270, down from CHF 310. The stock’s valuation has hit an all time high versus Demant and hearing aid peers, while the new product launch is known and currency is an increasing headwind, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONVY: